Rchr
J-GLOBAL ID：200901054919285746
Update date: Mar. 08, 2024
Tanaka Fumiaki
タナカ フミアキ | Tanaka Fumiaki
Affiliation and department：
Job title：
Professor
Research field (3)：
Neurology
, Medical biochemistry
, Pathobiochemistry
Research keywords (2)：
神経変性疾患の病態解明と治療法開発
, Elucidation of Pathogenesis of Neurodegenerative Disorders
Research theme for competitive and other funds (54)：
- 2023 - 2028 Elucidation of the pathogenesis of neuronal intranuclear inclusion disease and development of radical treatment
- 2022 - 2025 Analysis of pathological dynamics of membrane-less organelles in SALS
- 2021 - 2024 Development of disease-modifying therapy for spinocerebellar ataxia type 42 and elucidation of pathophysiological basis using optogenetic methods
- 2021 - 2024 扁桃体腫大を伴う側頭葉てんかんの病態背景の解明と新規治療法の開発
- 2021 - 2024 ミクログリアRIPK1の解析に基づくアミロイド-タウ連関解明と新規治療法の開発
- 2021 - 2024 新規イントロンリピート病CANVASの病態解析モデルの構築
- 2021 - 2024 単球系細胞から捉えた全身炎症による神経変性疾患の病態進展の機序解明
- 2020 - 2023 Development of innovative treatment for multiple sclerosis based on control of neurodegeneration and inflammation by applying function of LOTUS
- 2020 - 2023 VRと運動学習転移を用いたパーキンソン病における新しい運動訓練の開発
- 2019 - 2022 Genetical and pathological study of neuronal intranuclear inclusion disease
- 2019 - 2022 DEAD box RNA helicases are involved in sporadic ALS pathology
- 2018 - 2021 Elucidation of pathophysiology and development of treatment for spinocerebellar ataxia using a novel mouse model
- 2018 - 2021 Analysis of UBQLN2 based on loss of function model
- 2018 - 2021 Development of novel therapeutic strategy against neurodegenerative diseases by modulation of monocyte-lineage cell
- 2018 - 2021 Development of ALS therapy targeting LOTUS, a functional molecule for neuronal regeneration
- 2017 - 2020 Study of pathogenesis caused by hypouricemia in multiple system atrophy
- 2017 - 2019 Elucidation of abnormal accumulation of DDX17 in motor neuron of ALS
- 2017 - 2019 Clarification of the pathological mechanism of VGCC associated diseases
- 2016 - 2019 Development of objective evaluation method of cerebellar ataxia using 3D motion analysis system
- 2016 - 2018 Neural substrates of masked-face in Parkinson disease: A quantitative analysis of facial expression.
- 2016 - 2018 Elucidation of pathogenesis and development of new therapy for neurological disorder in multiple sclerosis
- 2015 - 2018 Analysis of genetic back ground and pathomechanism of spinocerebellar degeneration
- 2015 - 2017 Development of blood biomarker for neuronal injury
- 2015 - 2017 Analysis of polyglutamine aggregation protein in ALS/FTLD
- 2014 - 2017 Calcium-signaling abnormality of polyglutamine diseases
- 2014 - 2016 Elucidation of pathogeneis and development of a new biomarker associated with LOTUS in multiple sclerosis
- 2014 - 2016 Analysis of RNA binding proteins in polyglutamine disease
- 2013 - 2016 Integrated research of polyglutamine disease and ALS/FTLD by analysis of UBQLN2
- 2013 - 2016 Establishment of diagnosis method and analysis of genetic background of adult leukoencephalopathy patients with desktop next-generation sequencer
- 2012 - 2015 Identification of NIID causative gene with next generation sequencer
- 2010 - 2015 Exploration of disease-related genes based on personal genome analysis and elucidation of pathogenesis in ALS
- 2011 - 2014 Development of therapy targeting dysregulation of cell cycle and JNK pathway in polyglutamine diseases
- 2011 - 2014 Novel therapeutic approaches using the delivery of specific miRNAs for polyglutamine diseases
- 2009 - 2014 Development of Molecular Targeted Disease Modifying Therapy for Polyglutamine Diseases
- 2010 - 2012 Elucidation of pathogenesis and therapy development of sporadic ALS by disease model
- 2009 - 2011 Clarifying the mechanisms of amyloid deposition in familial amyloid polyneuropathy and its application to therapy
- 2008 - 2010 Therapeutic strategy for polyglutamine-mediated motor neuron disease via molecular chaperone-ubiquitin proteasome system
- 2009 - 2009 孤発性ALSのオートファジー機能解明と新規疾患モデルの確立
- 2005 - 2009 Development of pathogenesis-based therapy for polyglutamine diseases
- 2007 - 2008 Pathogenesis-based therapy development for polyglutamine diseases
- 2007 - 2008 Development of animal model for sporadic ALS
- 2007 - 2008 Research on the molecular pathogenetic mechanism of tissue-specific toxicity mediated by ALS-linked mutant SOD1
- 2007 - 2008 エオジン好性核内封入体(NIHID)の原因遺伝子の探索・同定
- 2006 - 2007 Development of therapies in polyglutamine diseases using hepatocyte growth factor (HGF)
- 2005 - 2006 Treatment of polyglutamine disease using small molecular compound
- 2005 - 2006 Exploration of Target Molecules Related to Pathogenesis and Development of Therapy for Sporadic ALS
- 2004 - 2005 Development of low-molecular-weight compound therapy for polyglutamine diseases
- 2005 - 遺伝性ニューロパチーの原因遺伝子探索と病態解明
- 2005 - 球脊髄性筋萎縮症の病態解明と治療法開発
- 2005 - 孤発性筋萎縮性側索硬化症の病態関連分子の探索と治療法開発
- 2003 - 神経疾患・腫瘍の統合分子医学的研究
- 1998 - 1999 Detection of Relating Molecules for the Pathology of Amyotrophic Lateral Screlosis by the Expressed-Gene Profiling
- 1998 - 1998 遺伝子発現プロファイリングによるパーキンソン病の病態関連遺伝子の同定
- 1995 - 遺伝性神経変性疾患の遺伝子診断
Show all
Papers (547)：
-
Naohiro Mouri, Haruki Koike, Yuki Fukami, Mie Takahashi, Satoru Yagi, Soma Furukawa, Masashi Suzuki, Yoshiyuki Kishimoto, Kenichiro Murate, Takamasa Nukui, et al. Granuloma, vasculitis, and demyelination in sarcoid neuropathy. European journal of neurology. 2024. 31. 1. e16091
-
Takuya Ikeda, Keita Takahashi, Minatsu Higashi, Hiroyasu Komiya, Tetsuya Asano, Akihiro Ogasawara, Shun Kubota, Shunta Hashiguchi, Misako Kunii, Kenichi Tanaka, et al. Lateral olfactory tract usher substance (LOTUS), an endogenous Nogo receptor antagonist, ameliorates disease progression in amyotrophic lateral sclerosis model mice. Cell death discovery. 2023. 9. 1. 454-454
-
Taishi Wada, Hiroshi Doi, Masaki Okubo, Mikiko Tada, Naohisa Ueda, Hidefumi Suzuki, Wakana Tominaga, Haruki Koike, Hiroyasu Komiya, Shun Kubota, et al. RNA foci in two bi-allelic RFC1 expansion carriers. Annals of neurology. 2023
-
小林 怜右, 古宮 裕泰, 小林 絵礼奈, 橋口 俊太, 高橋 慶太, 東山 雄一, 土井 宏, 田中 章景. 両側声帯麻痺を呈し気管切開術を要したβプロペラ蛋白関連神経変性症(BPAN)の57歳女性例. 臨床神経学. 2023. 63. 11. 775-775
-
細田 航平, 古宮 裕泰, 橋口 俊太, 田中 健一, 宮地 洋輔, 土井 宏, 竹内 英之, 田中 章景. 家系内で異なる臨床像を呈しVCP遺伝子バリアントを認めた家族性筋萎縮性側索硬化症の兄弟例. 臨床神経学. 2023. 63. 9. 605-605
ｍore...
MISC (849)：
-
浜田 智哉, 東山 雄一, 田中 章景. 【巨匠の神経心理学】Sperryの神経心理学. 脳神経内科. 2023. 98. 4. 598-606
-
水澤英洋, 塚本忠, 三條伸夫, 矢部一郎, 青木正志, 小野寺理, 田中章景, 道勇学, 浜口毅, 望月秀樹, et al. プリオン病及び遅発性ウイルス感染症に関する調査研究班 プリオン病のサーベイランス・感染予防に関する調査・研究の報告,JACOPの推進. プリオン病及び遅発性ウイルス感染症に関する調査研究班 令和3年度 総括・分担研究報告書(Web). 2022
-
渡辺 大祐, 馬場 泰尚, 田中 章景. 【脳神経内科診療における超音波】筋疾患診断への超音波. 脳神経内科. 2021. 95. 5. 586-594
-
田中 章景. Medical Scope 多発性硬化症の診断マーカー研究の進歩. Pharma Medica. 2021. 39. 11. 67-70
-
小笠原 陽大, 古宮 裕泰, 小川 有紀, 高橋 慶太, 竹内 英之, 田中 章景. 多発性硬化症治療薬siponimodのグリア細胞における作用機序. 神経免疫学. 2021. 26. 1. 129-129
ｍore...
Works (7)：
-
ポリグルタミン病の病態解明とそれに基づく治療法の開発
2005 - 2009
-
孤発性ALSの動物モデルの開発
2007 -
-
エオジン好性核内封入体(NIHID)の原因遺伝子の探索・同定
2007 -
-
老化に伴う神経変性疾患の長期縦断疫学研究:ALSについて
2005 - 2006
-
低分子化合物によるポリグルタミン病治療の開発ー臨床応用に向けて
2005 - 2006
ｍore...
Education (2)：
- 1980 - 1986 Nagoya University School of Medicine
- - 1986 Nagoya University Faculty of Medicine
Professional career (1)：
- PhD in medicine (Nagoya University)
Work history (10)：
- 2012 - 現在 Yokohama City University Graduate School of Medicine, Graduate
- 2007 - 2012 Nagoya University Graduate School of Medicine
- 2005 - 2007 Nagoya University Graduate School of Medicine
- 2005 - 2007 COE Associate Professor of Nagoya University
- 2007 - - Associate Professor of Neurology, Nagoya University
- 2007 - COE Associate Professor of Nagoya University
- 2003 - 2005 Nagoya University Graduate School of Medicine
- 2003 - 2005 Visiting Associate Professor of Nagoya University
- 1999 - 2002 米国国立衛生研究所(NIH)神経遺伝学部門 客員科学者
- 1999 - 2002 Visiting Scientist, Neurogenetics Branch, National Institute of Health (NIH), USA
Show all
Committee career (2)：
- 2006 - 日本神経学会 評議員
- 2005 - 日本末梢神経学会 評議員
Awards (1)：
Association Membership(s) (4)：
日本神経治療学会
, 日本内科学会
, 日本末梢神経学会
, 日本神経学会
